MedTrace Logo

A Clinical Trial of TQF6422 Injection in Overweight or Obese Healthy Subjects.

NCT07794111 · Status: NOT_YET_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 108

Last updated 2026-08-31

No results posted yet for this study

Summary

This is a placebo-controlled, double-blind trial to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple ascending doses of TQF6422 Injection in overweight or obese healthy participants.

Conditions

  • Obesity / Overweight

Interventions

DRUG

TQF6422 Injection

TQF6422 injection is an anti-ActRIIA/IIB monoclonal antibody.

DRUG

TQF6422 Placebo

A placebo matching TQF6422 Injection in appearance, dosage form, and route of administration, but containing no active ingredient.

Sponsors & Collaborators

  • Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-09-30
Primary Completion
2028-06-30
Completion
2028-06-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07794111 on ClinicalTrials.gov